--- title: "ApoB-containing lipoproteins: count, type, size, and risk of…" description: "Total apoB particle count is the primary indicator of atherosclerotic risk, with Lp(a) providing additional independent predictive value, while particle…" url: "https://magellanlongevity.com/study/d40289348.md" canonical: "https://magellanlongevity.com/study/d40289348.html" html: "https://magellanlongevity.com/study/d40289348.html" type: "study" study_key: "d40289348" journal: "Eur Heart J" year: 2025 pmid: "40289348" doi: "10.1093/eurheartj/ehaf207" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › ApoB-containing lipoproteins: count, type, size, and risk… **HTML version:** https://magellanlongevity.com/study/d40289348.html · **In the Magellan app:** https://magellanlongevity.com/#/study/d40289348 ## Citation | Field | Value | | --- | --- | | Journal | Eur Heart J | | Year | 2025 | | PMID | [40289348](https://pubmed.ncbi.nlm.nih.gov/40289348/) | | DOI | [10.1093/eurheartj/ehaf207](https://doi.org/10.1093/eurheartj/ehaf207) | | Study key | d40289348 | ## Takeaway Total apoB particle count is the primary indicator of atherosclerotic risk, with Lp(a) providing additional independent predictive value, while particle type or size offers little extra insight. ## The question Does the type or size of apoB-containing lipoprotein particles add predictive value for coronary artery disease (CAD) beyond the total apoB concentration? ## Hypothesis The study implicitly hypothesizes that the type or size of apoB particles might offer additional predictive value for CAD beyond the total apoB particle count. ## Methods A prospective analysis was conducted on 207,368 UK Biobank participants without prior atherosclerotic disease, diabetes, or active lipid-lowering therapy. Multivariable-adjusted Cox regression models were used to assess the association between incident CAD and nuclear magnetic resonance-measured apoB-P, concentrations of individual lipoprotein classes (VLDL, LDL), size subclasses, average particle diameter, and immunoassay-measured lipoprotein(a) [Lp(a)]. ## Results A one standard deviation (SD) increase in apoB-P was associated with a 33% higher CAD risk (HR: 1.33). VLDL particles showed a higher per-particle risk (HR per 100 nmol/L: 1.22) compared to LDL (HR per 100 nmol/L: 1.07), but this difference was balanced when considering relative particle abundance (LDL 91% vs VLDL 9% of total apoB-P), resulting in respective HR per 1-SD of 1.09 for LDL and 1.24 for VLDL. Particle diameter or size subclasses were not associated with CAD after apoB-P adjustment. Lp(a) showed a robust association even after apoB-P adjustment (HR: 1.18) and provided independent prognostic value for CAD (AUC: 0.769 vs 0.774, P < .001). ## Conclusion The total count of apoB-containing lipoprotein particles most accurately reflects lipid-related atherosclerotic risk, and this risk is largely unaffected by the major particle type (VLDL, LDL) or size. An elevated count of Lp(a) adds additional risk, suggesting that assessing atherogenic risk from dyslipidemia is best done by considering both apoB-P and Lp(a) concentrations. ## Limitations The abstract does not explicitly state any limitations of the study. ## Verbatim from the abstract > atherosclerotic risk is most accurately reflected by the total count of apoB particles ## Hazard Ratio for CAD per 1-SD Increase in Lipoprotein Parameters | Measure | Hazard Ratio | | --- | --- | | apoB-P | 1.33 | | VLDL particles (per 1-SD) | 1.24 | | LDL particles (per 1-SD) | 1.09 | | Lp(a) | 1.18 | *A one standard deviation increase in apoB-P was associated with a 33% higher CAD risk. VLDL and LDL particles, when adjusted for relative abundance, showed HRs of 1.24 and 1.09 respectively per 1-SD. Lp(a) also showed an independent association with CAD risk (HR: 1.18).* ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | NMR Lipoprotein Particle Test | — | — | ## Reference 1. **ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease** Eur Heart J 2025 · [PMID 40289348](https://pubmed.ncbi.nlm.nih.gov/40289348/) · [DOI 10.1093/eurheartj/ehaf207](https://doi.org/10.1093/eurheartj/ehaf207) > atherosclerotic risk is most accurately reflected by the total count of apoB particles ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/d40289348.html#page","url":"https://magellanlongevity.com/study/d40289348.html","name":"ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease","description":"Total apoB particle count is the primary indicator of atherosclerotic risk, with Lp(a) providing additional independent predictive value, while particle…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/d40289348.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"ApoB-containing lipoproteins: count, type, size, and risk…","item":"https://magellanlongevity.com/study/d40289348.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/d40289348.html#study","name":"ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease","headline":"ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease","datePublished":"2025","isPartOf":{"@type":"Periodical","name":"Eur Heart J"},"identifier":"PMID:40289348","url":"https://pubmed.ncbi.nlm.nih.gov/40289348/","sameAs":"https://doi.org/10.1093/eurheartj/ehaf207","abstract":"Total apoB particle count is the primary indicator of atherosclerotic risk, with Lp(a) providing additional independent predictive value, while particle type or size offers little extra insight."}]} ``` ## Related on Magellan Longevity - [Evidence: NMR LDL/HDL particle number](https://magellanlongevity.com/study/s150.md) - [The benefits of measuring the size and number of lipoprotein particles for…](https://magellanlongevity.com/study/d36522243.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).